| 000 | 01827 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515031538.0 | ||
| 264 | 0 | _c20070329 | |
| 008 | 200703s 0 0 eng d | ||
| 022 | _a1462-8902 | ||
| 024 | 7 |
_a10.1111/j.1463-1326.2006.00589.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRatner, R E | |
| 245 | 0 | 0 |
_aLong-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. _h[electronic resource] |
| 260 |
_bDiabetes, obesity & metabolism _cJul 2006 |
||
| 300 |
_a419-28 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xetiology |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aExenatide |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlycated Hemoglobin _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadverse effects |
| 650 | 0 | 4 |
_aLipids _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMetformin _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOverweight _xdrug effects |
| 650 | 0 | 4 |
_aPeptides _xadverse effects |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aVenoms _xadverse effects |
| 650 | 0 | 4 |
_aWeight Loss _xdrug effects |
| 700 | 1 | _aMaggs, D | |
| 700 | 1 | _aNielsen, L L | |
| 700 | 1 | _aStonehouse, A H | |
| 700 | 1 | _aPoon, T | |
| 700 | 1 | _aZhang, B | |
| 700 | 1 | _aBicsak, T A | |
| 700 | 1 | _aBrodows, R G | |
| 700 | 1 | _aKim, D D | |
| 773 | 0 |
_tDiabetes, obesity & metabolism _gvol. 8 _gno. 4 _gp. 419-28 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1463-1326.2006.00589.x _zAvailable from publisher's website |
| 999 |
_c16371582 _d16371582 |
||